CSBR (Champions Oncology) DeferredTaxAndRevenue: $10.00 Mil (As of Jan. 2026)


CSBR Champions Oncology Inc CSBR
61 GF Score
Price $6.07
GF Value $6.65
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Champions Oncology DeferredTaxAndRevenue?

Champions Oncology CSBR +3.16% 61 DeferredTaxAndRevenue is $10.00 Mil as of Jan. 2026. GuruFocus rates CSBR with a GF Score™ of 61/100 and a GF Value™ of $6.65 (Fairly Valued). The stock has 2 warning signs investors should review.

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Champions Oncology's current deferred tax and revenue for the quarter that ended in Jan. 2026 was $10.00 Mil.

Champions Oncology DeferredTaxAndRevenue Related Terms

Champions Oncology DeferredTaxAndRevenue Historical Data

* Premium members only.

The historical data trend for Champions Oncology's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Champions Oncology DeferredTaxAndRevenue Chart

Champions Oncology Annual Data
Trend Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24 Apr25
DeferredTaxAndRevenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.26 11.07 12.78 12.09 15.44

Champions Oncology Quarterly Data
Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26
DeferredTaxAndRevenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.92 15.44 14.43 12.34 10.00
CSBR
61GF Score
Champions Oncology Inc CSBR
DeferredTaxAndRevenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about DeferredTaxAndRevenue →
What does a DeferredTaxAndRevenue of $10.00 Mil mean?
Champions Oncology (CSBR) has a DeferredTaxAndRevenue of $10.00 Mil as of Jan. 2026. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on Champions Oncology.
Is Champions Oncology's DeferredTaxAndRevenue too high?
Champions Oncology's current DeferredTaxAndRevenue is $10.00 Mil. Overall, Champions Oncology has a GF Score™ of 61/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Champions Oncology's DeferredTaxAndRevenue compare to SEER and RLYB?
Champions Oncology's DeferredTaxAndRevenue of $10.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good DeferredTaxAndRevenue for a Biotechnology company?
A good DeferredTaxAndRevenue depends on the Biotechnology industry context. However, DeferredTaxAndRevenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high DeferredTaxAndRevenue mean?
A high DeferredTaxAndRevenue can signal that a stock is expensive relative to its fundamentals. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on Champions Oncology. Champions Oncology's current DeferredTaxAndRevenue is $10.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Champions Oncology stock overvalued right now?
Based on GuruFocus' analysis, Champions Oncology (CSBR) is currently considered Fairly Valued. The stock's GF Value™ is $6.65, compared to a current price of $6.07 — trading 8.8% below its estimated fair value. The current DeferredTaxAndRevenue is $10.00 Mil. Champions Oncology's overall GF Score™ is 61/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is DeferredTaxAndRevenue calculated?
DeferredTaxAndRevenue is calculated from a company's financial statements. For Champions Oncology (CSBR), the current DeferredTaxAndRevenue is $10.00 Mil as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Champions Oncology (CSBR) Overvalued in 2026?

Based on GuruFocus' analysis, Champions Oncology stock appears to be undervalued. The current stock price of $6.07 is trading 8.8% below its estimated GF Value™ of $6.65. GuruFocus considers Champions Oncology to be Fairly Valued.

Key valuation signals for CSBR:

  • DeferredTaxAndRevenue: $10.00 Mil
  • GF Value™: $6.65 vs. price of $6.07 (8.8% below fair value)
  • GF Score™: 61/100 with 2 warning signs

No single metric tells the full story. See the CSBR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Champions Oncology Business Description

Address One University Plaza, Suite 307, Hackensack, NJ, USA, 07601
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.
61GF Score

Get the complete analysis for CSBR

DeferredTaxAndRevenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.07
Price
$6.65
GF Value